Shanghai Junshi Biosciences Announces Nearly RMB 380 Million Capital Increase for Grit Biotechnology
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) disclosed that its subsidiary, Shanghai JunTop...
GRIT Biotechnology
Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors
US-based Inceptor Bio has entered into a partnership with Chinese firm GRIT Biotechnology to advance...
GRIT Biotechnology and Vitalgen BioPharma Partner on CRISPR-AaCas12bMAX Cell Therapies
China-based cell therapy specialists GRIT Biotechnology and Shanghai Vitalgen BioPharma Co., Ltd have entered into...
GRIT Biotechnology and Quangang Pharmaceutical Co., Ltd Partner to Develop TIL and IL-2 Combination Therapy
GRIT Biotechnology, a leading cell therapy specialist based in China, has entered into a strategic...
GRIT Biotechnology Secures RMB 400 Million in Series B Financing to Advance TIL Pipeline
China-based GRIT Biotechnology has announced the completion of a Series B financing round, raising RMB...
GRIT Biotechnology’s GT201 TIL Therapy Approved for Clinical Studies by China’s CDE
The Center for Drug Evaluation (CDE) website has indicated that GRIT Biotechnology, a China-based cell...